Outcome of etoposide and mitoxantrone for relapsed or refractory acute myeloid leukemia (RR-AML) in the modern era.
Zelia Bowman(West Virginia University), Aaron Cumpston(West Virginia University Hospitals), Abraham S. Kanate(HonorHealth), Nilay Shah(Levine Cancer Institute), Michael Craig(Edith Cowan University), Alex Shillingburg(West Virginia University), Ryan Caddell(West Virginia University Hospitals)
Cited by 0
Related Papers
Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2020|278
Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors
|Blood|2015|273
PD-1 blockade for relapsed lymphoma post–allogeneic hematopoietic cell transplant: high response rate but frequent GVHD
|Blood|2017|247
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy
|Transplantation and Cellular Therapy|2021|183